Trial Profile
A Phase 3 Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Comparing Adalimumab and Placebo in Adult Japanese Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms HOPEFUL-1
- Sponsors Abbott Japan; Eisai Co Ltd
- 23 Jun 2016 Results of safety analysis of this and other trials published in the Annals of the Rheumatic Diseases.
- 11 Jan 2013 Primary endpoint 'Total-Sharp-score' has been met.
- 02 Jan 2013 Planned patient number for extension study changed from 172 to 125, according to the ClinicalTrials.gov record (NCT01346501).